Deshpande, P.; Mohan, V.; Ingavale, D.; Mane, J.; Pore, M.; Thakurdesai Phd, P. (2017). "Preclinical Safety Assessment of Furostanol Glycoside-Based Standardized Fenugreek Seed Extract in Laboratory Rats". Journal of Dietary Supplements. 14 (5): 521–541. doi:10.1080/19390211.2016.1272659. PMID28156165. S2CID25932512.
Engelhardt JA, Dorato MA (August 2005). "The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)". Regul Toxicol Pharmacol. 42 (3): 265–274. doi:10.1016/j.yrtph.2005.05.004. PMID15979222.
Dorato, MA; Engelhardt, JA (August 2005). "The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s)". Regulatory Toxicology and Pharmacology. 42 (3): 265–74. doi:10.1016/j.yrtph.2005.05.004. PMID15979222.
Deshpande, P.; Mohan, V.; Ingavale, D.; Mane, J.; Pore, M.; Thakurdesai Phd, P. (2017). "Preclinical Safety Assessment of Furostanol Glycoside-Based Standardized Fenugreek Seed Extract in Laboratory Rats". Journal of Dietary Supplements. 14 (5): 521–541. doi:10.1080/19390211.2016.1272659. PMID28156165. S2CID25932512.
Engelhardt JA, Dorato MA (August 2005). "The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)". Regul Toxicol Pharmacol. 42 (3): 265–274. doi:10.1016/j.yrtph.2005.05.004. PMID15979222.
Dorato, MA; Engelhardt, JA (August 2005). "The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s)". Regulatory Toxicology and Pharmacology. 42 (3): 265–74. doi:10.1016/j.yrtph.2005.05.004. PMID15979222.